Literature DB >> 1783533

A double blind randomized pilot trial of naloxone in the treatment of acute ischemic stroke.

F Federico1, V Lucivero, P Lamberti, A Fiore, C Conte.   

Abstract

Attention has focused on naloxone, an opiate receptor antagonist, because of its potential benefit in reversing neurological damage after acute cerebral ischemia. To evaluate the safety and possible efficacy of high-dose naloxone in ischemic stroke patients we planned a double blind pilot study. Between January 1989 and May 1990 24 patients were randomly assigned to the naloxone or placebo group according to age and neurological deficit. Naloxone was given in a loading dose of 5 mg/kg over 10 minutes followed by a 24-hour infusion at the rate of 3.5 mg/kg/h. 10 patients experienced minor side effects but none of them had to discontinue the treatment. 9 patients improved: 6 in the naloxone group and 3 in the placebo group, but no significant difference was found using the non parametric Mann-Whitney test. Our study suggests that naloxone is safe at the dose used, but the results do not support the planning of similar trials on a larger scale.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1783533     DOI: 10.1007/bf02336951

Source DB:  PubMed          Journal:  Ital J Neurol Sci        ISSN: 0392-0461


  39 in total

1.  Effect of beta-endorphin on calcium uptake in the brain.

Authors:  F Guerrero-Munoz; M de Lourdes Guerrero; E L Way; C H Li
Journal:  Science       Date:  1979-10-05       Impact factor: 47.728

2.  Reversal of induced ischemic neurologic deficit in gerbils by the opiate antagonist naloxone.

Authors:  Y Hosobuchi; D S Baskin; S K Woo
Journal:  Science       Date:  1982-01-01       Impact factor: 47.728

3.  A phase I trial of naloxone treatment in acute spinal cord injury.

Authors:  E S Flamm; W Young; W F Collins; J Piepmeier; G L Clifton; B Fischer
Journal:  J Neurosurg       Date:  1985-09       Impact factor: 5.115

4.  A double blind trial of naloxone in the treatment of acute stroke.

Authors:  R J Fallis; M Fisher; R A Lobo
Journal:  Stroke       Date:  1984 Jul-Aug       Impact factor: 7.914

5.  Diagnosis of reversible versus irreversible cerebral ischemia by the intravenous administration of naloxone.

Authors:  B Estañol; F Aguilar; T Corona
Journal:  Stroke       Date:  1985 Nov-Dec       Impact factor: 7.914

6.  Improvement in injury induced hypocalcia by high-dose naloxone intervention.

Authors:  B T Stokes; G Hollinden; P Fox
Journal:  Brain Res       Date:  1984-01-02       Impact factor: 3.252

7.  Naloxone administration to patients with acute stroke.

Authors:  J Jabaily; J N Davis
Journal:  Stroke       Date:  1984 Jan-Feb       Impact factor: 7.914

8.  Treatment of experimental stroke with opiate antagonists. Effects on neurological function, infarct size, and survival.

Authors:  D S Baskin; Y Hosobuchi; J C Grevel
Journal:  J Neurosurg       Date:  1986-01       Impact factor: 5.115

9.  A dose-escalation study of large doses of naloxone for treatment of patients with acute cerebral ischemia.

Authors:  H P Adams; C P Olinger; W G Barsan; M J Butler; N R Graff-Radford; T G Brott; J Biller; H Damasio; T Tomsick; M Goldberg
Journal:  Stroke       Date:  1986 May-Jun       Impact factor: 7.914

10.  Effects of enkephalins, morphine, and naloxone on pial arteries during perivascular microapplication.

Authors:  M Wahl
Journal:  J Cereb Blood Flow Metab       Date:  1985-09       Impact factor: 6.200

View more
  7 in total

Review 1.  Clinical trials for cytoprotection in stroke.

Authors:  Lise A Labiche; James C Grotta
Journal:  NeuroRx       Date:  2004-01

Review 2.  Limiting neurological damage after stroke: a review of pharmacological treatment options.

Authors:  S J Read; T Hirano; S M Davis; G A Donnan
Journal:  Drugs Aging       Date:  1999-01       Impact factor: 3.923

3.  Does naloxone reinstate secondary hyperalgesia in humans after resolution of a burn injury? A placebo-controlled, double-blind, randomized, cross-over study.

Authors:  Manuel P Pereira; Mads U Werner; Thomas K Ringsted; Michael C Rowbotham; Bradley K Taylor; Joergen B Dahl
Journal:  PLoS One       Date:  2013-05-31       Impact factor: 3.240

4.  Effects of target-controlled infusion of high-dose naloxone on pain and hyperalgesia in a human thermal injury model: a study protocol: A randomized, double-blind, placebo-controlled, crossover trial with an enriched design.

Authors:  Anders D Springborg; Elisabeth K Jensen; Bradley K Taylor; Mads U Werner
Journal:  Medicine (Baltimore)       Date:  2016-11       Impact factor: 1.889

5.  Effect of a high-dose target-controlled naloxone infusion on pain and hyperalgesia in patients following groin hernia repair: study protocol for a randomized controlled trial.

Authors:  M P Pereira; M U Werner; J B Dahl; Manuel Pedro Pereira; Mads Utke Werner; Joergen Berg Dahl
Journal:  Trials       Date:  2015-11-10       Impact factor: 2.279

6.  Post-stroke Intranasal (+)-Naloxone Delivery Reduces Microglial Activation and Improves Behavioral Recovery from Ischemic Injury.

Authors:  Jenni E Anttila; Katrina Albert; Emily S Wires; Kert Mätlik; Lisa C Loram; Linda R Watkins; Kenner C Rice; Yun Wang; Brandon K Harvey; Mikko Airavaara
Journal:  eNeuro       Date:  2018-04-18

7.  High-dose naloxone: Effects by late administration on pain and hyperalgesia following a human heat injury model. A randomized, double-blind, placebo-controlled, crossover trial with an enriched enrollment design.

Authors:  Anders Deichmann Springborg; Elisabeth Kjær Jensen; Mads Kreilgaard; Morten Aagaard Petersen; Theodoros Papathanasiou; Trine Meldgaard Lund; Bradley Kenneth Taylor; Mads Utke Werner
Journal:  PLoS One       Date:  2020-11-12       Impact factor: 3.752

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.